JP5970459B2 - がん診断用バイオマーカーに対する骨髄細胞の使用 - Google Patents

がん診断用バイオマーカーに対する骨髄細胞の使用 Download PDF

Info

Publication number
JP5970459B2
JP5970459B2 JP2013528723A JP2013528723A JP5970459B2 JP 5970459 B2 JP5970459 B2 JP 5970459B2 JP 2013528723 A JP2013528723 A JP 2013528723A JP 2013528723 A JP2013528723 A JP 2013528723A JP 5970459 B2 JP5970459 B2 JP 5970459B2
Authority
JP
Japan
Prior art keywords
cancer
mdsc
patients
treatment
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013528723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013539857A (ja
JP2013539857A5 (enExample
Inventor
シン，ハープリート
ヴァルター，シュテフェン
メンドルツィク，レジーナ
ブロンテ，ヴィンチェンツォ
マンドルッツァト，スザンナ
Original Assignee
イマティクス バイオテクノロジーズ ゲーエムベーハー
イマティクス バイオテクノロジーズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イマティクス バイオテクノロジーズ ゲーエムベーハー, イマティクス バイオテクノロジーズ ゲーエムベーハー filed Critical イマティクス バイオテクノロジーズ ゲーエムベーハー
Publication of JP2013539857A publication Critical patent/JP2013539857A/ja
Publication of JP2013539857A5 publication Critical patent/JP2013539857A5/ja
Application granted granted Critical
Publication of JP5970459B2 publication Critical patent/JP5970459B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G01N33/575—
    • G01N33/57535—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5751—
    • G01N33/57525—
    • G01N33/5753—

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2013528723A 2010-09-21 2011-09-21 がん診断用バイオマーカーに対する骨髄細胞の使用 Expired - Fee Related JP5970459B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38478410P 2010-09-21 2010-09-21
GB1015765.9 2010-09-21
US61/384,784 2010-09-21
GBGB1015765.9A GB201015765D0 (en) 2010-09-21 2010-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer
PCT/EP2011/066397 WO2012038463A2 (en) 2010-09-21 2011-09-21 Use of myeloid cell biomarkers for the diagnosis of cancer

Publications (3)

Publication Number Publication Date
JP2013539857A JP2013539857A (ja) 2013-10-28
JP2013539857A5 JP2013539857A5 (enExample) 2014-10-30
JP5970459B2 true JP5970459B2 (ja) 2016-08-17

Family

ID=43065538

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013528723A Expired - Fee Related JP5970459B2 (ja) 2010-09-21 2011-09-21 がん診断用バイオマーカーに対する骨髄細胞の使用

Country Status (10)

Country Link
US (1) US9671404B2 (enExample)
EP (1) EP2619585B1 (enExample)
JP (1) JP5970459B2 (enExample)
KR (1) KR20130137635A (enExample)
CN (1) CN103180739B (enExample)
CA (1) CA2811070A1 (enExample)
EA (1) EA201390413A1 (enExample)
GB (1) GB201015765D0 (enExample)
SG (2) SG188543A1 (enExample)
WO (1) WO2012038463A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
EP3682896A1 (en) * 2011-04-28 2020-07-22 University of Southern California Human myeloid derived suppressor cell cancer markers
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
US20160030558A1 (en) * 2013-03-13 2016-02-04 Health Research, Inc. Enhancement of vaccines
CN103743907B (zh) * 2013-07-24 2015-04-15 北京大学人民医院 测定造血干细胞移植后患者骨髓微循环环境评测的试剂盒、系统及方法
WO2015048748A1 (en) * 2013-09-30 2015-04-02 Board Of Regents, The University Of Texas System Myeloid-derived suppressor cell-specific peptides for diagnostic and therapeutic use
CN103626846B (zh) * 2013-11-08 2016-06-01 上海交通大学 与MDSCs特异性结合的配体多肽及药物输送系统
EP3012271A1 (en) * 2014-10-24 2016-04-27 Effimune Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases
WO2016210241A1 (en) * 2015-06-26 2016-12-29 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
MX2018002640A (es) * 2015-09-02 2018-06-20 Syndax Pharmaceuticals Inc Seleccion de pacientes para la terapia de combinacion.
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
EP4438626A3 (en) 2016-04-14 2024-12-04 OSE Immunotherapeutics New anti-sirpa antibodies and their therapeutic applications
NZ754222A (en) 2016-12-08 2022-02-25 Immatics Biotechnologies Gmbh T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CN107102127B (zh) * 2017-04-07 2019-08-06 东北师范大学 一种人体外周血中单核样髓源抑制细胞的检测方法
AU2018269039B2 (en) 2017-05-19 2025-05-15 Syndax Pharmaceuticals, Inc. Combination therapies
WO2018221820A1 (ko) * 2017-06-02 2018-12-06 이종균 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
US11713356B2 (en) 2017-10-13 2023-08-01 Ose Immunotherapeutics Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
KR102216725B1 (ko) * 2017-12-29 2021-02-17 연세대학교 산학협력단 면역 항암 요법에 대한 치료 반응 예측 방법
CA3091468A1 (en) 2018-03-13 2019-09-19 Ose Immunotherapeutics Use of anti-human sirpa v1 antibodies and method for producing anti-sirpa v1 antibodies
WO2019217484A1 (en) 2018-05-07 2019-11-14 Syndax Pharmaceuticals, Inc. Selection of patients for combination therapy
CN110501483B (zh) * 2019-07-25 2020-12-29 同济大学 一种中草药活性的检测方法
TR202003833A1 (tr) 2020-03-12 2021-09-21 Hacettepe Ueniversitesi Rektoerluek Mi̇yeloi̇d kökenli̇ baskilayici hücrelere özgü bi̇yobeli̇rteç paneli̇
EP4347653A1 (en) 2021-06-04 2024-04-10 Boehringer Ingelheim International GmbH Anti-sirp-alpha antibodies
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用
CN117030580B (zh) * 2023-09-15 2024-07-16 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） LDNs在坏死性小肠结肠炎诊断中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US20040136973A1 (en) * 2002-11-07 2004-07-15 Eliezer Huberman Human stem cell materials and methods
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB0820698D0 (en) * 2008-11-12 2008-12-17 Ludwig Inst Cancer Res Uses of immunomodulators

Also Published As

Publication number Publication date
CN103180739B (zh) 2016-08-03
CN103180739A (zh) 2013-06-26
SG188543A1 (en) 2013-04-30
JP2013539857A (ja) 2013-10-28
US9671404B2 (en) 2017-06-06
WO2012038463A3 (en) 2012-07-26
EP2619585A2 (en) 2013-07-31
GB201015765D0 (en) 2010-10-27
KR20130137635A (ko) 2013-12-17
SG10201510470WA (en) 2016-01-28
WO2012038463A2 (en) 2012-03-29
EA201390413A1 (ru) 2013-07-30
US20120070461A1 (en) 2012-03-22
CA2811070A1 (en) 2012-03-29
EP2619585B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
JP5970459B2 (ja) がん診断用バイオマーカーに対する骨髄細胞の使用
Edwards et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti–PD-1 treatment
Ye et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer
Mimeault et al. Molecular biomarkers of cancer stem/progenitor cells associated with progression, metastases, and treatment resistance of aggressive cancers
CN103384827B (zh) 用于预测癌症免疫治疗效果的生物标记
JP5774309B2 (ja) 癌マーカーおよび治療ターゲット
US10738119B2 (en) Combination therapy for hepatocellular carcinoma
JP7571872B2 (ja) 膀胱がん又は腎臓がん対象者の転帰の予測
US9851357B2 (en) Method for the prognosis of survival time of a patient suffering from a solid cancer
US20210017607A1 (en) Methods of Predicting Responsiveness to Cancer Therapies
Heng et al. High expression of tumor HLA-DR predicts better prognosis and response to anti-PD-1 therapy in laryngeal squamous cell carcinoma
Nie et al. Mechanisms of immunotherapy resistance in small cell lung cancer
JP2024151758A (ja) 肝臓癌を治療する方法、治療に対する応答を予測する方法、及び肝臓癌の治療中の有害作用を予測する方法
JP7255896B2 (ja) シクロホスファミド療法に対する応答者の予測
Yu et al. Elevated circulating CD19+ lymphocytes predict survival advantage in patients with gastric cancer
Raphael et al. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma
Gerard et al. Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms
WO2010123124A1 (ja) 固形がんの再発および予後因子、およびその臨床利用
Camcı et al. Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer
HK1183096A (en) Use of myeloid cell biomarkers for the diagnosis of cancer
HK1183096B (en) Use of myeloid cell biomarkers for the diagnosis of cancer
WO2019055930A1 (en) METHODS OF IDENTIFYING MYELOMA TUMOR INITIATOR CELLS AND TARGETED THERAPY
Sesma et al. Peripheral blood TCRβ repertoire, IL15, IL2 and soluble ligands for NKG2D activating receptor predict efficacy of ICI in lung cancer
JP7042753B2 (ja) 免疫チェックポイント阻害剤の投与対象となる個体の選択方法
Kostine Defining the immune microenvironment in sarcoma: could immunotherapy be part of the treatment strategy in sarcoma patients?

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140909

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140909

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150408

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160411

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160711

R150 Certificate of patent or registration of utility model

Ref document number: 5970459

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees